{"success":true,"data":{"pressRelease":{"id":"153594","rtpr_id":"nPn7rVZJPa-20260928","ticker":"CAPR","exchange":"NASDAQ","all_tickers":["CAPR"],"title":"Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR","author":"PR Newswire","published_at":"2026-09-28T06:10:00.041Z","article_body":"Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR\nPR Newswire\n\nNEW YORK, Sept. 28, 2026\n\nNEW YORK, Sept. 28, 2026 /PRNewswire/ -- The DJS Law Group\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783746-1&h=2612927211&u=https%3A%2F%2Fdjslawllp.com%2F&a=The+DJS+Law+Group)\n reminds investors of a class action lawsuit against Capricor Therapeutics,\nInc. (\"Capricor\" or \"the Company\") (NASDAQ: CAPR\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783746-1&h=768044304&u=https%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2FCAPR&a=CAPR)\n) for violations of §§10(b) and 20(a) of the Securities Exchange Act of\n1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of CAPR during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: December 17, 2025 to July 26, 2026\n\nDEADLINE: September 28, 2026\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Capricor modified the statistical\nanalysis plan used in the analysis of clinical data for Deramiocel. The\nCompany failed to secure the FDA's agreement to this change before it\nresubmitted a Biologics License Application for the drug. Based on these\nfacts, Capricor's public statements were false and materially misleading\nthroughout the class period.\n\nIf you are a shareholder who suffered a loss, contact us to participate\n(mailto:David@djslawllp.com) .\n\nWHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor\nreturn through balanced counseling and aggressive advocacy. As one of the\nfounding partners of Schall Brown & Schwartz LLP (schallfirm.com), David\nSchwartz specializes in securities class actions, corporate governance\nlitigation, and domestic/international M&A appraisals. Our clients are\nsome of the largest and most sophisticated hedge funds and alternative asset\nmanagers in the world. The litigation claims of our clients are\nextraordinarily valuable assets that demand respect, focus, and results.\n\nJoin the case (mailto:David@djslawllp.com)  to recover your losses.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\nCONTACT:\nDavid J. Schwartz\nDJS Law Group\n274 White Plains Road, Suite 1\nEastchester, NY 10709\nPhone: 914-206-9742\nEmail: David@djslawllp.com (mailto:David@djslawllp.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/capricor-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--capr-302891021.html\n(https://www.prnewswire.com/news-releases/capricor-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--capr-302891021.html)\n\nSOURCE DJS Law Group LLP\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn7rVZJPa-20260928","title":"Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR","author":"PR Newswire","ticker":"CAPR","created":"2026-09-28T06:10:00.041Z","tickers":["CAPR"],"exchange":"NASDAQ","article_body":"Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR\nPR Newswire\n\nNEW YORK, Sept. 28, 2026\n\nNEW YORK, Sept. 28, 2026 /PRNewswire/ -- The DJS Law Group\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783746-1&h=2612927211&u=https%3A%2F%2Fdjslawllp.com%2F&a=The+DJS+Law+Group)\n reminds investors of a class action lawsuit against Capricor Therapeutics,\nInc. (\"Capricor\" or \"the Company\") (NASDAQ: CAPR\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4783746-1&h=768044304&u=https%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2FCAPR&a=CAPR)\n) for violations of §§10(b) and 20(a) of the Securities Exchange Act of\n1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of CAPR during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: December 17, 2025 to July 26, 2026\n\nDEADLINE: September 28, 2026\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Capricor modified the statistical\nanalysis plan used in the analysis of clinical data for Deramiocel. The\nCompany failed to secure the FDA's agreement to this change before it\nresubmitted a Biologics License Application for the drug. Based on these\nfacts, Capricor's public statements were false and materially misleading\nthroughout the class period.\n\nIf you are a shareholder who suffered a loss, contact us to participate\n(mailto:David@djslawllp.com) .\n\nWHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor\nreturn through balanced counseling and aggressive advocacy. As one of the\nfounding partners of Schall Brown & Schwartz LLP (schallfirm.com), David\nSchwartz specializes in securities class actions, corporate governance\nlitigation, and domestic/international M&A appraisals. Our clients are\nsome of the largest and most sophisticated hedge funds and alternative asset\nmanagers in the world. The litigation claims of our clients are\nextraordinarily valuable assets that demand respect, focus, and results.\n\nJoin the case (mailto:David@djslawllp.com)  to recover your losses.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\nCONTACT:\nDavid J. Schwartz\nDJS Law Group\n274 White Plains Road, Suite 1\nEastchester, NY 10709\nPhone: 914-206-9742\nEmail: David@djslawllp.com (mailto:David@djslawllp.com)\n\nView original\ncontent:https://www.prnewswire.com/news-releases/capricor-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--capr-302891021.html\n(https://www.prnewswire.com/news-releases/capricor-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--capr-302891021.html)\n\nSOURCE DJS Law Group LLP\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-28T06:10:00.090862371Z","server_sent_at_ms":1790575800090},"received_at":"2026-09-28T06:10:00.142Z","source_url":"https://www.prnewswire.com/news-releases/capricor-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--capr-302891021.html"},"analysis":{"id":"142391","press_release_id":"153594","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["alleged FDA protocol change (statistical analysis plan modification) without prior FDA agreement on Deramiocel BLA resubmission"],"eventType":"legal_litigation","narrative":"The DJS Law Group issued a solicitation notice for a securities class action against Capricor Therapeutics, alleging misleading statements under Exchange Act sections 10(b) and 20(a).\n\nThe complaint centers on claims that Capricor modified the statistical analysis plan for Deramiocel clinical data without securing prior FDA agreement before resubmitting the Biologics License Application.\n\nThe class period is December 17, 2025 to July 26, 2026, with a September 28, 2026 lead-plaintiff deadline; this is law-firm marketing rather than a new issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; underlying Deramiocel/FDA issue may warrant monitoring on issuer filings."},"keyFigures":{},"quotedText":"Capricor modified the statistical analysis plan used in the analysis of clinical data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug.","namedEntities":{"people":[{"name":"David Schwartz","role":"founding partner, DJS Law Group"}],"products":["Deramiocel"],"companies":[{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"target of class action"},{"name":"DJS Law Group","relationship":"plaintiff law firm"},{"name":"U.S. Securities and Exchange Commission","relationship":"regulator referenced in complaint"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by the DJS Law Group reminding investors of a lead-plaintiff deadline. No certified class, no settlement, and no new issuer disclosure."},"tickerRelevance":{"others":[],"primary":"CAPR"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"The DJS Law Group issued a solicitation notice for a securities class action against Capricor Therapeutics, alleging misleading statements under Exchange Act sections 10(b) and 20(a).\n\nThe complaint centers on claims that Capricor modified the statistical analysis plan for Deramiocel clinical data without securing prior FDA agreement before resubmitting the Biologics License Application.\n\nThe class period is December 17, 2025 to July 26, 2026, with a September 28, 2026 lead-plaintiff deadline; this is law-firm marketing rather than a new issuer disclosure.","key_figures":{},"named_entities":{"people":[{"name":"David Schwartz","role":"founding partner, DJS Law Group"}],"products":["Deramiocel"],"companies":[{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"target of class action"},{"name":"DJS Law Group","relationship":"plaintiff law firm"},{"name":"U.S. Securities and Exchange Commission","relationship":"regulator referenced in complaint"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T06:10:05.200Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":4981,"modelName":"glm-5.3-flashx"}}